Drug Profile
Cetuximab biosimilar - Reliance Life Sciences
Alternative Names: R-TPR-033; R-TPR-033 - Reliance Life SciencesLatest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 31 Jan 2019 No development reported - Phase-III for Head and neck cancer (Late-stage disease, Locally recurrent, Metastatic disease) in India (IV)
- 14 Jan 2019 Reliance Life Sciences terminates a phase III trial in Head and neck cancer (Late-stage disease, Metastatic disease, Locally recurrent) in India (IV) (CTRI2015-06-005909)
- 25 Jun 2015 Phase-III clinical trials in Head and neck cancer (Late-stage disease, Metastatic disease, Locally recurrent) in India (IV) (CTRI2015-06-005909)